Efimova Evgeniya V, Gainetdinov Raul R, Budygin Evgeny A, Sotnikova Tatyana D
a Institute of Translational Biomedicine, St. Petersburg State University , St. Petersburg , Russia ;
b Skolkovo Institute of Science and Technology , Skolkovo , Moscow Region , Russia ;
J Neurogenet. 2016 Mar;30(1):5-15. doi: 10.3109/01677063.2016.1144751.
The dopamine transporter (DAT) plays an important homeostatic role in the control of both the extracellular and intraneuronal concentrations of dopamine, thereby providing effective control over activity of dopaminergic transmission. Since brain dopamine is known to be involved in numerous neuropsychiatric disorders, investigations using mice with genetically altered DAT function and thus intensity of dopamine-mediated signaling have provided numerous insights into the pathology of these disorders and novel pathological mechanisms that could be targeted to provide new therapeutic approaches for these disorders. In this brief overview, we discuss recent investigations involving animals with genetically altered DAT function, particularly focusing on translational studies providing new insights into pathology and pharmacology of dopamine-related disorders. Perspective applications of these and newly developed models of DAT dysfunction are also discussed.
多巴胺转运体（DAT）在控制细胞外和神经元内多巴胺浓度方面发挥着重要的稳态作用，从而有效控制多巴胺能传递的活性。由于已知脑内多巴胺参与多种神经精神疾病，利用多巴胺转运体功能发生遗传改变从而多巴胺介导信号强度改变的小鼠进行的研究，为这些疾病的病理机制以及可能成为这些疾病新治疗方法靶点的新病理机制提供了诸多见解。在本简要综述中，我们讨论了近期涉及多巴胺转运体功能发生遗传改变的动物的研究，尤其关注为多巴胺相关疾病的病理学和药理学提供新见解的转化研究。还讨论了这些模型以及新开发的多巴胺转运体功能障碍模型的潜在应用。
